Acne has been linked to a number of conditions including depression, anxiety, heart disease and diabetes, and is one of the leading causes of death in the United States.

But a new study has found that using Proactiv acne treatment reduces inflammation and acne severity in people with type 1 diabetes and may even reduce the risk of developing type 2 diabetes.

The study, which was published in the Journal of the American Medical Association, found that participants taking Proactiv for up to four weeks experienced a slight reduction in the number of flares and the number and severity of acne flare-ups in the first two months, according to the Journal.

“Our findings show that Proactiv treatment can reduce the frequency and severity in acne flare ups and inflammation, and possibly reduce the incidence of type 2 Diabetes, even in people who are already on insulin or who are on a high-carbohydrate diet,” study researcher and lead author Dr. Mandy A. Schmitt said in a press release.

“Proactiv is an effective acne treatment for patients with Type 1 diabetes, a disease that has been associated with increased inflammation, metabolic issues and impaired glucose control.”

The study is the first to show that a new class of compounds called non-covalent fatty acids (NFCAs), known as amphiphilic fatty acids, or MACAs, can help control acne inflammation and inflammation in people.”MACAs have been shown to be effective at blocking the effects of proinflammatory cytokines, including TNF-alpha, IL-1β, IL10, IL6, IL17, and chemokines, such as IL-2 and IL-6, that can trigger the inflammatory response,” study co-author Dr. Mark E. Gorton, of the University of California, San Diego, said in the press release .

“The study found that MACAs reduced the inflammatory effects of Proactiv and did not significantly alter the inflammatory responses associated with Proactiv or a standard combination of oral anti-inflammatory medications.”

Researchers tested the efficacy of the treatment in over 200 patients who had been diagnosed with type 2 diabetic diabetes, with varying degrees of inflammation.

The participants were given a low-dose Proactiv formulation called “ProActiv” (200 mg/day) or a low dose of ProActiv (200 ml/day), which was given in a capsule.

After four weeks, the participants were monitored for changes in inflammation, type 2 acne severity, and changes in lipid profile.

“After four months, the study showed that ProActiv significantly reduced the number, severity, frequency and number and type of flares in type 2 insulin-resistant type 1 diabetic patients compared with a control group of individuals with insulin-normal type 2,” Schmitt wrote.

The researchers found that Proact treatment significantly reduced overall inflammation and increased overall lipid profile and lipid levels in participants, as well as increased levels of antioxidants and decreased levels of inflammation-causing chemokine TNF.

Proactiv also reduced the severity and frequency of acne flares in participants compared with the control group.

“These results suggest that Proactive may help to reduce the severity of the inflammatory changes that are associated with insulin resistance, which are important in type 1 type 2, type 1-derived and type 2-derived diabetes,” Schumann wrote.

“This treatment may also reduce the potential for type 2 Type 1 type 1 diabetics to develop type 2 disease in the future.”

The researchers noted that Proaction did not affect the results of participants with type-1 diabetes or type-2 diabetes.

“There is some evidence that ProACT may be effective for reducing inflammation and potentially improving insulin sensitivity, but the mechanisms by which this may occur remain unclear,” the researchers wrote.

“The authors recommend future research to better understand how Proactiv may reduce the inflammatory, metabolic and inflammation-related effects of the disease and whether it is able to reduce both.”

Follow Elizabeth Palermo on Twitter @techEpalermo or Google+.

Follow Live Science @livescience, Facebook & Google+.

Originally published at Live Science.